Skip to main content
GKOS logo

Glaukos Corporation (GKOS) Stock Price & Analysis

Glaukos Corporation (GKOS) — MoonshotScore 38/100 (Weak band), calculated Nov 22, 2026. Price $237.31 (-0.33%), as of the Nov 20, 2026 trading session; market cap $14.1B.

Educational signal · not a buy or sell recommendation · How to read this

$237.31 −$0.79 (-0.33%) Market Cap $14.1B

Glaukos Corporation · GKOS · NYSE · Healthcare · Medical - Devices

Research dated 2026-09-13: Glaukos sells ophthalmic therapies built around micro-scale implants: glaucoma stents used with cataract surgery, a standalone stent system for refractory disease, and targeted drug delivery through iDose TR. The case depends on whether rapid product-revenue growth and rich gross profit can outpace research and commercial spending long enough to produce durable operating profit and cash generation.

Price as of Nov 20, 2026

Key Statistics

38 of 100

MoonshotScore v2 · Glaukos (GKOS)

Weak
Business Quality Solid (70)
Financial Safety Sound (78)
Valuation Rich (35)
Growth Durability Growing (64)
Momentum Surging (100)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality and a strong balance sheet, but an expensive valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Sound; Valuation: Rich; Growth Durability: Growing; Momentum: Surging.

  • EPS beat 1 of the last 4 reports
  • Altman Z 31.44 · Piotroski F 4
  • ROE -22.8% · ROA -3.9% · current ratio 4.57

Helping: business quality, balance-sheet strength, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for GKOS (58 recorded, newest six shown)
RecordedScoreBand
39Weak
38Weak
38Weak
38Weak
38Weak
38Weak

The score was 38 in the stored Nov 21, 2026 snapshot and remains 38 in the current publication computed Nov 22, 2026 (0); the largest pillar moves were Momentum +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$237.31
Change on the day-0.33%
52-week range$87.32–$255.19
Market capitalisation$14.1B
Price / earnings (trailing)353.54
Shares traded on the day1.09M
Beta (volatility vs the S&P 500)0.69

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 20, 2026: low $75, high $246, latest $237. $246 $75 high $246 Oct 17, 2025 Nov 20, 2026 · $237 $87Oct 17, 2025$88Oct 31, 2025$90Nov 14, 2025$106Nov 28, 2025$109Dec 12, 2025$116Dec 26, 2025$113Jan 9, 2026$120Jan 23, 2026$113Feb 6, 2026$120Feb 20, 2026$108Mar 6, 2026$101Mar 20, 2026$113Apr 2, 2026$125Apr 17, 2026$140May 1, 2026$144May 15, 2026$103May 29, 2026$127Jun 12, 2026$144Jun 26, 2026$153Jul 10, 2026$154Jul 24, 2026$180Aug 7, 2026$185Aug 21, 2026$177Sep 4, 2026$164Sep 18, 2026$164Oct 2, 2026$165Oct 16, 2026$238Oct 30, 2026$246Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Glaukos (GKOS): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Moderate
Valuation Weak
Growth Durability Moderate
Momentum Strong

Legends Council

4 lenses, 4 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 22, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Moderate
ROE Negative
Gross Margin Strong

Read on: Nov 20, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 22, 2026, except a card that shows its own read date.

1 · What is it?

What is Glaukos (GKOS), and what does it report?

Short answer · as of

Glaukos is not merely a surgical-device manufacturer. Its portfolio spans implanted glaucoma devices and sustained pharmaceutical delivery, with ophthalmologists adopting the products through procedure-based care and the company reaching customers through direct sales and distributors.

Reported revenue is consolidated product revenue rather than a current platform-by-platform scorecard. A historical segment view was dominated by glaucoma, with corneal health much smaller, so the economic engine remains adoption of glaucoma therapies even as the broader pipeline reaches into corneal and retinal disease.

2 · Latest results

What do the latest results show for Glaukos (GKOS)?

Revenue has risen across successive reported periods and accelerated sharply in the latest period. Gross profit advanced faster than operating expenses, allowing the operating loss to narrow even as research and commercial spending climbed; the net result nevertheless remained negative.

Recent reported revenue has also exceeded consensus repeatedly, while adjusted earnings have generally compared favorably with expectations. The observable mechanism is stronger aggregate product demand through Glaukos's sales channels; the consolidated figures do not support assigning the acceleration to a particular therapy.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$134M-$16M-$0.28 (diluted)
Q4 FY2025$143M-$134M-$2.32 (diluted)
Q1 FY2026$151M-$20M-$0.34 (diluted)
Q2 FY2026$186M-$18M-$0.31 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Glaukos (GKOS)?

Short answer

The MoonshotScore pillars rate business quality, balance-sheet strength, positive momentum as strengths.

Liquidity is the clearest financial strength. Cash and short-term investments exceed total debt, the cash balance rose from the preceding period, and recent annualized cash use suggests substantial funding capacity if the current burn profile holds.

Cash conversion is not yet dependable: operating cash flow has alternated between positive and negative periods, annual net losses have expanded, and trailing operating and net margins remain below zero. High gross margin offers operating leverage, but research and selling costs still absorb more than the gross profit left after product costs.

Valuation adds a separate risk. Net cash is modest beside the company's market value, while price-to-sales and price-to-book ratios imply that investors already attach considerable value to future adoption and profitability.

Data-derived red flags

  • Negative return on equity (-22.8%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Rich valuation — a P/E of 353.54 runs well above the Healthcare sector’s ~20.60x, leaving little room for a miss.
4 · What to check next?

What should you watch next at Glaukos (GKOS)?

Short answer · as of

The stored analyst-target capture is expired, so a current target watchpoint is unavailable.

Watch whether revenue holds near the newly elevated run rate, gross margin preserves its recent improvement, and operating losses keep narrowing while research and selling costs rise. Positive operating cash flow would carry more weight if it persists rather than continuing the recent alternating pattern.

Consensus expects revenue to retreat from the latest peak while the loss per share narrows at the forthcoming report. Longer-range estimates assume continued revenue expansion and eventual positive earnings, making delivery against that progression a practical test of whether commercial scale is catching up with spending.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Glaukos compare with its peers?

Short answer

Glaukos's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Glaukos combines procedure-linked glaucoma stents with sustained intraocular drug delivery on a shared micro-scale platform. That hybrid model differs from a conventional device company because adoption can come from cataract-associated implants, standalone intervention for refractory glaucoma, or recurring therapeutic delivery rather than from a single hardware cycle.

Its current financial profile is equally distinctive: high gross margin and fast revenue expansion coexist with persistent research intensity, operating losses, and uneven cash generation. The business is therefore being valued less on present earnings than on the platform's ability to spread commercial and development costs across a growing ophthalmic portfolio.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Oscar Health, Inc. (OSCR) Named competitor$24.73 Nov 20, 2026$7.68B97 5-pillar Nov 22, 2026
Globus Medical, Inc. (GMED) Same industry, near in market value$66.89 Nov 20, 2026$8.86B95 5-pillar Nov 22, 2026
Penumbra, Inc. (PEN) Same industry, near in market value$319.12 Nov 20, 2026$12.6B93 5-pillar Nov 22, 2026
DexCom, Inc. (DXCM) Same industry, near in market value$79.32 Nov 20, 2026$29.6B93 5-pillar Nov 22, 2026
STERIS plc (STE) Same industry, near in market value$255.76 Nov 20, 2026$24.8B88 5-pillar Nov 22, 2026
Smith & Nephew plc (SNN) Same industry, near in market value$29.83 Nov 20, 2026$12.5B85 5-pillar Nov 22, 2026
Insulet Corporation (PODD) Same industry, near in market value$133.17 Nov 20, 2026$9.24B85 5-pillar Nov 22, 2026
Align Technology, Inc. (ALGN) Same industry, near in market value$155.17 Nov 20, 2026$10.9B83 5-pillar Nov 22, 2026
Zimmer Biomet Holdings, Inc. (ZBH) Same industry, near in market value$101.10 Nov 20, 2026$19.1B80 5-pillar Nov 22, 2026
Koninklijke Philips N.V. (PHG) Same industry, near in market value$28.61 Nov 20, 2026$28.0B79 5-pillar Nov 22, 2026
Bio-Rad Laboratories, Inc. (BIO) Same industry, near in market value$358.90 Nov 20, 2026$9.65B78 5-pillar Nov 22, 2026
Bruker Corporation (BRKR) Named competitor$56.46 Nov 20, 2026$8.62B59 5-pillar Nov 22, 2026
Glaukos (GKOS) — this page$237.31$14.1B38

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Last captured analyst target range, low to high (expired, captured Nov 18, 2026)
$150.00 – $255.00
Last captured analyst target (expired, captured Nov 18, 2026)
$225.55
Last captured median analyst target (expired, captured Nov 18, 2026)
$240.00

Historical target record · Captured · Capture expired; not a current watchpoint.

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 12, 2026

Transactions
97
Identified insiders
11
Purchases
0
Sales
38
Other transactions
59

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held GKOS in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported GKOS in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Common Questions About GKOS (Healthcare)

The last 2 questions are answered from this page's own dated data, not from the research.

How is iDose TR different from the iStent family?

The iStent family improves fluid outflow through implanted micro-bypass devices, while iDose TR uses an injectable implant to deliver glaucoma medication inside the eye. Glaukos therefore participates in glaucoma care through mechanical intervention and targeted pharmaceutical delivery.

Does Glaukos depend on cataract surgery for glaucoma adoption?

The established iStent products are inserted during cataract surgery, tying that part of the portfolio to procedure volumes and physician selection. iStent Infinite is intended for standalone use in refractory glaucoma, while iDose TR adds a drug-delivery route outside the cataract-linked stent model.

Why is Glaukos still losing money while revenue is rising?

Research and selling costs continue to consume the company's substantial gross profit. Revenue growth has recently narrowed the operating loss, but annual net losses and trailing margins show that scale has not yet produced sustained profitability.

Can Glaukos fund expansion of iDose TR and iStent Infinite?

Cash and short-term investments exceed debt, and the recent burn-rate cross-check indicates ample runway if spending and cash conversion remain comparable. Uneven operating cash flow and persistent losses mean that capacity depends on continued commercial progress and cost discipline.

What is the GKOS stock price today?

The last price recorded for Glaukos Corporation (GKOS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the GKOS price target?

The last analyst consensus price target we captured for Glaukos Corporation (GKOS), with its FMP capture date, is listed under Analyst targets & estimates on this page. That capture has expired, so read it as historical, not as a current target. Targets are analyst opinions, not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 20 figures on this page — 1 from SEC filings and earnings calls, 15 from Financial Modeling Prep (FMP), 2 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set
  • 1. What is Glaukos (GKOS), and what does it report?: Business description; Quarterly income statement (USD thousands); Revenue by segment; Most recent periodic reports
  • 2. What do the latest results show for Glaukos (GKOS)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Reported versus estimated, last 8 quarters; Business description; Recent SEC filings
  • 3. What are the financial strengths and risks for Glaukos (GKOS)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash runway cross-check (ours); Operating cash flow by quarter (USD millions); Annual revenue and net result (USD millions); Trailing twelve-month ratio set; Cash against market value; Distress and quality screens
  • 4. What should you watch next at Glaukos (GKOS)?: Next earnings report; Analyst revenue and earnings estimates (average); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Trailing twelve-month ratio set
  • 5. How does Glaukos compare with its peers?: Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set; Cash against market value
  • FAQ: How is iDose TR different from the iStent family?: Business description
  • FAQ: Does Glaukos depend on cataract surgery for glaucoma adoption?: Business description
  • FAQ: Why is Glaukos still losing money while revenue is rising?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Trailing twelve-month ratio set
  • FAQ: Can Glaukos fund expansion of iDose TR and iStent Infinite?: Business description; Cash, investments and debt; Cash and investment components; Cash runway cross-check (ours); Operating cash flow by quarter (USD millions); Annual revenue and net result (USD millions)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold GKOS

Funds in our ETF coverage that list GKOS among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
iShares Russell 2000 ETF (IWM)0.33%